Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Trevena Closes $40 Million Revenue-based Financing with CBC Affiliate

publication date: Apr 18, 2022

Trevena, a Philadelphia-area CNS biopharma, closed a $40 million revenue-based financing from an affiliate of R-Bridge Healthcare Fund, which is allied with CBC. The funding is tied to future China milestones of Trevena’s Olyinvyk®, a novel injected Schedule II opioid. In 2018, Trevena out-licensed China rights for Olyinvyk to Jiangsu Nhwa Pharma. Trevena will receive $15 million upfront, another $15 million after the first China sale of Olyinvyk® and $10 million after a financing or commercial milestone. The R-Bridge entity will be repaid by receiving all of Trevena’s China revenues from Nhwa, plus a percentage of Trevena’s US Olyinvyk revenues. More details....

Stock Symbol: (NSDQ: TRVN)

Share this with colleagues: